Brokers Set Expectations for CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Brookline Capital Management issued their FY2024 EPS estimates for Perspective Therapeutics in a research report issued on Monday, March 10th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.88) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.41) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.59) EPS and FY2026 earnings at ($2.04) EPS.

A number of other equities research analysts have also recently issued reports on CATX. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Scotiabank started coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.13.

Perspective Therapeutics Trading Up 6.4 %

Perspective Therapeutics stock opened at $2.66 on Wednesday. The business’s 50 day simple moving average is $3.17 and its 200 day simple moving average is $7.44. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05.

Institutional Trading of Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after purchasing an additional 298,778 shares during the period. WealthPlan Investment Management LLC bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $4,530,000. State Street Corp grew its holdings in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Janus Henderson Group PLC raised its position in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares in the last quarter. Finally, FMR LLC raised its position in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.